Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced a time change for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place at 10:30 AM ET on September 9, 2025, at the Lotte New York Palace Hotel.
Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings during the conference, which runs from September 8-10, 2025. Interested parties can access the presentation via webcast.
Anixa Biosciences (NASDAQ: ANIX), azienda biotecnologica specializzata nel trattamento e nella prevenzione del cancro, ha comunicato una variazione dell'orario della propria presentazione al H.C. Wainwright 27th Annual Global Investment Conference. La presentazione si terr脿 ora alle 10:30 AM ET il 9 settembre 2025 presso il Lotte New York Palace Hotel.
Mike Catelani, Presidente e Chief Financial Officer, presenter脿 e sar脿 disponibile per incontri one-to-one durante la conferenza, che si svolge dall'8 al 10 settembre 2025. La presentazione sar脿 accessibile anche via webcast.
Anixa Biosciences (NASDAQ: ANIX), una compa帽铆a biotecnol贸gica especializada en el tratamiento y la prevenci贸n del c谩ncer, ha anunciado un cambio de horario para su presentaci贸n en la H.C. Wainwright 27th Annual Global Investment Conference. La presentaci贸n tendr谩 lugar ahora a las 10:30 AM ET el 9 de septiembre de 2025 en el Lotte New York Palace Hotel.
Mike Catelani, presidente y director financiero, ofrecer谩 la presentaci贸n y estar谩 disponible para reuniones uno a uno durante la conferencia, que se celebra del 8 al 10 de septiembre de 2025. Las partes interesadas podr谩n acceder a la presentaci贸n v铆a webcast.
Anixa Biosciences (NASDAQ: ANIX), 鞎� 旃橂 氚� 鞓堧癌鞚� 鞝勲鞙茧 頃橂姅 氚旍澊鞓ろ厡韥� 旮办梾鞚� H.C. Wainwright 27th Annual Global Investment Conference鞐愳劀鞚� 氚滍憸 鞁滉皠 氤�瓴届潉 氚滍憸頄堨姷雼堧嫟. 氚滍憸電� 2025雲� 9鞗� 9鞚� 霃欕秬鞁滉皠(ET) 鞓れ爠 10鞁� 30攵�搿� 氤�瓴诫悩鞐堨溂氅� 鞛レ唽電� 搿嵃 雺挫殨 韺半Μ鞀� 順疙厰鞛呺媹雼�.
Mike Catelani 雽�響� 瓴� 斓滉碃鞛毂呾瀯鞛�(CFO)臧� 氚滍憸毳� 歆勴枆頃橂┌, 2025雲� 9鞗� 8鞚茧秬韯� 10鞚缄箤歆� 鞐措Μ電� 旎嵓霟办姢 旮瓣皠 霃欖晥 鞚茧寑鞚� 氙疙寘鞐愲弰 鞚戫暊 鞓堨爼鞛呺媹雼�. 甏�鞁� 鞛堧姅 攵勲摛鞚� 鞗轨簮鞀ろ姼毳� 韱淀暣 氚滍憸毳� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
Anixa Biosciences (NASDAQ: ANIX), soci茅t茅 de biotechnologie sp茅cialis茅e dans le traitement et la pr茅vention du cancer, a annonc茅 un changement d'horaire pour sa pr茅sentation 脿 la H.C. Wainwright 27th Annual Global Investment Conference. La pr茅sentation aura d茅sormais lieu 脿 10h30 ET le 9 septembre 2025 au Lotte New York Palace Hotel.
Mike Catelani, pr茅sident et directeur financier, assurera la pr茅sentation et sera disponible pour des r茅unions individuelles pendant la conf茅rence, qui se tient du 8 au 10 septembre 2025. Les personnes int茅ress茅es pourront suivre la pr茅sentation via webcast.
Anixa Biosciences (NASDAQ: ANIX), ein Biotechnologieunternehmen, das sich auf Krebsbehandlung und -pr盲vention spezialisiert hat, hat eine Zeit盲nderung f眉r seine Pr盲sentation auf der H.C. Wainwright 27th Annual Global Investment Conference angek眉ndigt. Die Pr盲sentation findet nun am 9. September 2025 um 10:30 Uhr ET im Lotte New York Palace Hotel statt.
Mike Catelani, Pr盲sident und CFO, wird die Pr盲sentation halten und w盲hrend der Konferenz, die vom 8. bis 10. September 2025 stattfindet, f眉r pers枚nliche Einzelgespr盲che zur Verf眉gung stehen. Interessierte k枚nnen die Pr盲sentation per Webcast verfolgen.
- None.
- None.
Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.
Details of the presentation are as follows:
Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 10:30 AM ET
Location: Kennedy I 鈥� 4th Floor, Lotte New York Palace Hotel
Webcast:
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit 聽or follow Anixa on , , and .
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
[email protected]
408-708-9808
View original content to download multimedia:
SOURCE Anixa Biosciences, Inc.
FAQ
When is Anixa Biosciences (ANIX) presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Anixa Biosciences (ANIX) at the H.C. Wainwright Conference?
How can investors watch Anixa Biosciences' (ANIX) H.C. Wainwright Conference presentation?
Will Anixa Biosciences (ANIX) management be available for meetings at the conference?
